Skip to main content

Table 2 Univariate and multivariate Cox Regression analyses for PFS and OS in MM

From: Clinical significance of genetic profiling based on different anatomic sites in patients with mucosal melanoma who received or did not receive immune checkpoint inhibitors

Variable

PFS

OS

Univariate

Multivariate

Univariate

Multivariate

HR

95.0% CI

Pa

HR

95.0% CI

Pa

HR

95.0% CI

Pa

HR

95.0% CI

Pa

Gender (Female)

1.21

0.66–2.23

0.542

   

1.30

0.71–2.36

0.394

   

Age (≥ 56 years)

0.76

0.41–1.39

0.371

   

0.89

0.49–1.61

0.702

   

Site (Esophagus)

5.24

2.30-11.92

0.000

   

6.50

2.84–14.87

0.000

   

Site (Small bowel)

9.74

1.20–79.60

0.034

   

3.92

0.50-31.27

0.180

   

Site (Esophagus + Small bowel)

4.98

2.53–9.78

0.000

4.78

2.42–9.45

0.000

5.27

2.68–10.36

0.000

5.26

2.51–11.03

0.000

Stage (III - IV)

1.46

0.70–3.06

0.314

   

1.23

0.61–2.51

0.570

   

Mitotic activity (≥ 3 /mm2)

1.12

0.57–2.19

0.744

   

1.22

0.64–2.34

0.547

   

Mitotic activity (≥ 10 /mm2)

1.65

0.71–3.84

0.246

   

2.30

1.05–5.06

0.039

2.76

1.22–6.25

0.015

Morphology (Spindle cell)

0.61

0.18–2.07

0.432

   

0.58

0.18–1.93

0.377

   

Ulceration

1.22

0.15–9.80

0.849

   

0.82

0.22–3.13

0.773

   

BRAF mutation

1.26

0.56–2.87

0.578

   

1.14

0.51–2.56

0.754

   

KIT mutation

0.91

0.43–1.90

0.793

   

1.18

0.56–2.48

0.661

   

RAS mutation

1.50

0.66–3.38

0.339

   

1.32

0.59–2.97

0.450

   

TP53 mutation

1.14

0.45–2.92

0.784

   

0.96

0.41–2.27

0.923

   

NF1 mutation

1.42

0.65–3.11

0.380

   

1.38

0.63–3.02

0.420

   

SF3B1 mutation

0.70

0.24–1.99

0.498

   

0.93

0.32–2.68

0.897

   

FBXW7 mutation

1.58

0.55–4.51

0.397

   

1.53

0.55–4.31

0.418

   

CBL mutation

3.96

1.65–9.52

0.002

3.54

1.46–8.56

0.005

3.70

1.54–8.90

0.004

5.57

2.04–15.19

0.001

TERT mutation

1.24

0.44–3.50

0.687

   

1.80

0.39–3.05

0.880

   

ATRX mutation

1.64

0.58–4.63

0.348

   

1.46

0.52–4.09

0.475

   

ICIs treatment b

0.56

0.30–1.04

0.064

   

0.40

0.22–0.75

0.004

0.39

0.20–0.75

0.008

  1. Abbreviations CI, confidence interval; HR, hazard ratio; PFS, progression-free Survival; OS, overall survival; MM, mucosal melanomas; CBL, Casitas B-lineage lymphoma; ICI, immune checkpoint inhibitor; aP values were from Cox proportional hazard regression models; b indicates that patients received ICIs throughout the treatment for OS while before the progression for PFS
Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us